Trial Profile
Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Gastric cancer; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms GastroLap
- 17 Jan 2020 This trial has been completed in Germany as per Eudra CT record
- 09 Sep 2016 Discrepancy in status. NCT reports as discontinued, Eudra reports as suspended and German Clinical Trial Register reports as active, no longer recruiting. Retained it as per NCT, as it is a reliable source.
- 24 Apr 2013 Planned end date changed from 1 Jul 2015 to 1 Oct 2013 as reported by ClinicalTrials.gov.